Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.
The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.
Pacira BioSciences, Inc. (PCRX) reported third-quarter 2026 revenue of $176.653 million, compared with $179.516 million a year earlier, and net income of $28.521 million versus $5.432 million. Operating income was $22.272 million, compared with $6.362 million. Nine-month net income was $36.090 million versus $5.397 million, and operating cash flow was $133.210 million.
On October 30, Peach Purchaser Sub Inc., a wholly owned subsidiary of Viatris Inc., commenced a tender offer for each issued and outstanding Pacira share at $36.50 in cash per share, net of applicable withholding taxes and without interest. The merger is expected to close before the end of 2026, subject to customary conditions, including tenders and affiliated holdings totaling at least one share more than 50% of issued and outstanding shares. If completed, Pacira would become a wholly owned Viatris subsidiary and cease to be publicly traded. Pacira may owe Viatris a $62.0 million termination fee in specified circumstances.
Pacira completed the iovera° divestiture to Zimmer on July 31, 2026, and received $73.6 million after purchase-price adjustments. The agreement provides for up to an additional $70.0 million tied to revenue milestones through 2031.
Pacira BioSciences, Inc. (PCRX) said Viatris Inc., through its wholly owned subsidiary Peach Purchaser Sub Inc., commenced a tender offer on October 30, 2026 to purchase all issued and outstanding Pacira common shares for $36.50 per share in cash, net of applicable withholding taxes and without interest. The Agreement and Plan of Merger was entered into on October 8, 2026.
Under the agreement, as soon as practicable after the offer is consummated, and subject to its terms and conditions, Peach Purchaser Sub will merge with and into Pacira under Section 251(h) of the Delaware General Corporation Law. Pacira will survive the merger as a wholly owned subsidiary of Viatris.
Because of the proposed Offer and Merger, Pacira will not issue an earnings release or hold a conference call for the quarter ended September 30, 2026. Pacira withdrew its previously issued 2026 financial guidance and will not provide further updates to that guidance while the proposed transaction is pending.
Pacira BioSciences, Inc. (PCRX) reported that Chief Financial Officer Shawn Cross had 9,540 common shares withheld by the issuer on October 30, 2026, to cover tax withholding obligations upon vesting of a restricted stock unit award. The transaction was classified as a tax-withholding disposition.
Pacira BioSciences, Inc. amended its Schedule 14D-9 by adding the “Pacira BioSciences, Inc. Employee FAQ,” first used November 3, 2026. The amendment says the prior statement remains unchanged except for the updates described.
Vanguard Capital Management reported beneficial ownership of 1,923,614 Pacira BioSciences, Inc. common shares, equal to 4.82% of the class. The reported amount reflects securities attributed to Vanguard Capital Management LLC and specified affiliates or business divisions, including fund holdings subject to its dispositive power and client holdings subject to affiliates’ or divisions’ voting and/or dispositive power.
Vanguard Capital Management reported sole voting power over 297,029 shares and sole dispositive power over 1,923,614 shares; shared voting and dispositive power were both reported as zero.
Pacira BioSciences, Inc. (PCRX) said its board unanimously recommends that stockholders accept Viatris’ tender offer and tender their shares for $36.50 per share in cash, net of applicable withholding taxes and without interest. The offer is scheduled to expire one minute following 11:59 p.m. Eastern Time on November 16, 2026, subject to extension under the merger agreement. It is for all outstanding shares; after the offer is consummated, Purchaser will merge into Pacira under Section 251(h), without a stockholder meeting or vote, and Pacira will become a wholly owned Viatris subsidiary.
Pacira reported 39,957,678 shares issued and outstanding as of October 23, 2026. Its board determined the transaction is fair to and in the best interests of Pacira and its stockholders; Goldman Sachs provided an opinion that the cash consideration was fair from a financial point of view. Pacira also disclosed directors’ and executive officers’ interests, including their shareholdings and cash settlement of eligible options and equity awards at the Effective Time. Options with exercise prices at or above $36.50 are canceled without consideration; other outstanding options and RSUs and PSUs are converted into cash under the merger agreement.
Pacira BioSciences, Inc. is the subject of a tender offer by Peach Purchaser Sub Inc., a wholly owned subsidiary of Viatris Inc., for all outstanding common shares at $36.50 per share. The offer provides for cash consideration, net of applicable withholding taxes and without interest, under its terms and conditions.
Pacira advised Viatris that 39,957,678 shares were issued and outstanding as of October 23, 2026, excluding 9,018,591 shares held in treasury. The Offer to Purchase is dated October 30, 2026; the merger agreement among Pacira, Viatris and the purchaser is dated October 8, 2026.
Pacira BioSciences, Inc. (PCRX) is the issuer named in a Schedule 13D amendment stating that the reporting persons ceased to be beneficial owners of more than 5% of the common shares on October 8, 2026. Each reporting-person cover page lists 0 shares and 0% beneficial ownership.
The reporting persons are DOMA Perpetual Capital Management LLC, DOMA1 LLC, DOMA Perpetual LO Equity Master Fund LP, DOMA Perpetual Partners GP LLC, Pedro Escudero, The John Templeton Foundation and DOMA2 LLC.
Pacira BioSciences, Inc. (PCRX) Senior Vice President, Finance Lauren Riker exercised options for 6,000 common shares on October 8, 2026, at an exercise price of $32.35 per share, then sold 6,000 shares at $36.32 per share. The exercise and sale were made under a Rule 10b5-1 trading plan adopted March 12, 2026. The reported option position after the exercise was 0 shares, and the option's expiration date was December 7, 2026.